Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00252538 · ClinicalTrials.gov registry record

Genetic and Biochemical Markers of Interferon-Induced Depression.

A clinical trial of Depression, sponsored by US Department of Veterans Affairs.

Completed
Registry status
133
Enrollment target
3
Study locations

NCT00252538: Completed study of Depression, sponsored by US Department of Veterans Affairs.

NCT00252538 is a study of Depression that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 133 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00252538, a study of Depression, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
133 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to identify predictors and associated biochemical markers of interferon-induced depression. It is hypothesized that genetic variation in genes related to the serotonergic system may predict vulnerability to interferon-induced depression.

Primary Outcome

Structured psychiatric interviews and symptom rating scales for depression were used as primary outcome measures to determine the association between phenotype (interferon-induced depression) and genotype (genes that confer risk of interferon-induced depression). Genes of interest related to development of depression and antiviral treatment response that may confer risk for interferon induced depression were examined. this was a multi-site study and included participants from several hospital se

Conditions Studied

Study Locations (3)

California

  • VA Medical Center, Long Beach - Long Beach

Minnesota

  • VA Medical Center, Minneapolis - Minneapolis

Oregon

  • VA Medical Center, Portland - Portland

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2006-04
Est. Completion 2009-09
US Department of Veterans Affairs

632 total trials

What the finished NCT00252538 record still lists

NCT00252538 is an observational study that tracks outcomes without assigning an intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 0 interventions.

NCT00252538 reports a single indexed study location in California, Minnesota, Oregon.

Frequently Asked Questions

What is clinical trial NCT00252538 about?

NCT00252538 is a clinical study titled "Genetic and Biochemical Markers of Interferon-Induced Depression.". The purpose of this study is to identify predictors and associated biochemical markers of interferon-induced depression. It is hypothesized that genetic variation in genes related to the serotonergic system may predict vulnerability to interferon-induced depression.

What is the current status of trial NCT00252538?

This trial is currently completed. The enrollment target is 133 participants. The study started on 2006-04. Estimated completion is 2009-09.

What conditions does trial NCT00252538 study?

This clinical trial studies the following conditions: Depression.

Who is sponsoring clinical trial NCT00252538?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00252538 being conducted?

This trial has 3 study locations across California, Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00252538's enrollment target sits among peer trials

133 281st of 679 higher than 399 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04276870 · 133 participants · Phase 2

    Orphan Indications for CD19 Redirected Autologous T Cells

  • NCT04671771 · 133 participants · NA

    A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

  • NCT05610085 · 133 participants · Phase 2

    A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

  • NCT06206486 · 133 participants

    The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00252538, the US trial registry maintained by the National Library of Medicine. NCT00252538 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.